RESUMEN
PURPOSE: We performed this study to determine the value of pharmacoerection with PGE1 for measurement of conduction velocity in the dorsal penile nerve and to identify the change in sensation in the glans penis between th pre-erection and posterection state. MATERIALS AND METHODS: We studied 14 patients with psychogenic impotence and premature ejaculation (mean age 45.2+/-6.5 years) who had no evidence of neurologic deficit and responded with a full erection lasting more than 1 hour to PGE1 injection. We measured penile length, penile temperature, sensory threshold of the glans penis to electrical stimulation, BCRL, pudendal sensory evoked potential (SEP), and dorsal nerve conduction velocity and amplitude before, directly after, and 1 hour after erection induced using PGE1(15~20 microgram). RESULTS: Neither PGE1 nor prolonged erection had any effect on the sensory threshold of glans penis, BCRL, pudendal SEP, or amplitude of the dorsal verve. Only the dorsal nerve conduction velocity changed. We could check the conduction velocity after erection in therr cases in which these values were not available at rest. CONCLUSIONS: Given the absence of change in the sensory condition of the glans penis, pharmacoerection using PGE1 has no effect on premature ejaculation except to prolong the erection state. Pharmacoerection seems to be the best method of calculating dorsal nerve sensory conduction velocity and amplitude, It can replace th normal erection state and also help in obtaining a recordable potential when this measurement is technically difficult at rest.
Asunto(s)
Humanos , Masculino , Alprostadil , Estimulación Eléctrica , Disfunción Eréctil , Potenciales Evocados , Conducción Nerviosa , Manifestaciones Neurológicas , Pene , Eyaculación Prematura , Nervio Pudendo , Sensación , Umbral SensorialRESUMEN
PURPOSE: We performed this study to determine the value of pharmacoerection with PGE1 for measurement of conduction velocity in the dorsal penile nerve and to identify the change in sensation in the glans penis between th pre-erection and posterection state. MATERIALS AND METHODS: We studied 14 patients with psychogenic impotence and premature ejaculation (mean age 45.2+/-6.5 years) who had no evidence of neurologic deficit and responded with a full erection lasting more than 1 hour to PGE1 injection. We measured penile length, penile temperature, sensory threshold of the glans penis to electrical stimulation, BCRL, pudendal sensory evoked potential (SEP), and dorsal nerve conduction velocity and amplitude before, directly after, and 1 hour after erection induced using PGE1(15~20 microgram). RESULTS: Neither PGE1 nor prolonged erection had any effect on the sensory threshold of glans penis, BCRL, pudendal SEP, or amplitude of the dorsal verve. Only the dorsal nerve conduction velocity changed. We could check the conduction velocity after erection in therr cases in which these values were not available at rest. CONCLUSIONS: Given the absence of change in the sensory condition of the glans penis, pharmacoerection using PGE1 has no effect on premature ejaculation except to prolong the erection state. Pharmacoerection seems to be the best method of calculating dorsal nerve sensory conduction velocity and amplitude, It can replace th normal erection state and also help in obtaining a recordable potential when this measurement is technically difficult at rest.